C-reactive protein and venous thromboembolism

Journal:Thrombosis and Haemostasis
ISSN:0340-6245
DOI:http://dx.doi.org/10.1160/TH09-04-0274
Issue:2009: 102/4 (Oct) pp. 611-798
Pages:615-619

C-reactive protein and venous thromboembolism

A prospective investigation in the ARIC cohort

Aaron R. Folsom1; Pamela L. Lutsey1; Brad C. Astor2; Mary Cushman3

1Division of Epidemiology & Community Health, School of Public Health, University of Minnesota, Minneapolis, Minnesota, USA; 2Department
of Epidemiology, The Johns Hopkins Bloomberg School of Public Health, The Johns Hopkins University, Baltimore, Maryland, USA;
3Department of Medicine, University of Vermont, Burlington, Vermont, USA; 3Department of Pathology, University of Vermont, Burlington,
Vermont, USA

Summary

The role of inflammation in the causation of venous thromboembolism (VTE) is uncertain. In 10,505 participants of the Atherosclerosis Risk in Communities (ARIC) Study, we assessed the association of the systemic inflammation marker, elevated C-reactive protein (CRP), with incidence of VTE (n=221) over a median of 8.3 years of follow-up. Adjusted for age, race, and sex, the hazard ratios of VTE across quintiles of CRP were 1.0, 1.61, 1.16, 1.56, and 2.31 (p for trend p<0.0007). For CRP above the upper 10 percentile (≥8.55 mg/L), compared with the lowest 90% of CRP values, the hazard ratio of VTE was 2.07 (95% CI 1.47, 2.94). Further adjustment for baseline hormone replacement therapy, diabetes, and body mass index attenuated the hazard ratios only slightly. For example, the adjusted hazard ratio of VTE was 1.76 (95% CI 1.23, 2.52) for CRP above versus below the 90th percentile. In conclusion, this prospective, populationbased study suggests elevated CRP is independently associated with increased risk of VTE.

Keywords

Venous thrombosis, C-reactive protein, prospective study, pulmonary embolus

DOI

http://dx.doi.org/10.1160/TH09-04-0274

You may also be interested in...

1.

A. R. Folsom (1), P. L. Lutsey (1), S. R. Heckbert (2), M. Cushman (3)

Thrombosis and Haemostasis 2010 104 1: 100-104

http://dx.doi.org/10.1160/TH09-12-0856

2.

Beate Luxembourg1; Joern Schmitt2; Marek Humpich3; Matthias Glowatzki4; Dejan Dressler1; Erhard Seifried5;
Edelgard Lindhoff-Last1

Thrombosis and Haemostasis 2009 102 4: 668-675

http://dx.doi.org/10.1160/TH-09-02-0104

3.

Elena Rossi, Tommaso Za, Angela Ciminello, Giuseppe Leone, Valerio De Stefano

Thrombosis and Haemostasis 2008 99 6: 1030-1034

http://dx.doi.org/10.1160/TH08-02-0069



Articles

You've 553 Article(s) in your Basket.

TH 107.5

Clinical Focus on GPIIb/IIIa inhibitors: In the May issue of Thrombosis and Haemostasis Armstrong...

TH 107.4

The April 2012 issue of Thrombosis and Haemostasis TH 107.4 is a Theme Issue by A. Schober, T....

Thrombosis and Haemostasis official organ of Spanish Society for Thrombosis and Haemostasis

Thrombosis and Haemostasis, founded in 1957, has become the official organ of the Spanish Society...